Search

Your search keyword '"Hong, Seungpyo"' showing total 608 results
Start Over Author "Hong, Seungpyo"
608 results on '"Hong, Seungpyo"'

2. Control of a fly-mimicking flyer in complex flow using deep reinforcement learning

Author

Hong, Seungpyo, Kim, Sejin, and You, Donghyun

Subjects
Computer Science - Machine Learning, Physics - Fluid Dynamics
Abstract

An integrated framework of computational fluid-structural dynamics (CFD-CSD) and deep reinforcement learning (deep-RL) is developed for control of a fly-scale flexible-winged flyer in complex flow. Dynamics of the flyer in complex flow is highly unsteady and nonlinear, which makes modeling the dynamics challenging. Thus, conventional control methodologies, where the dynamics is modeled, are insufficient for regulating such complicated dynamics. Therefore, in the present study, the integrated framework, in which the whole governing equations for fluid and structure are solved, is proposed to generate a control policy for the flyer. For the deep-RL to successfully learn the control policy, accurate and ample data of the dynamics are required. However, satisfying both the quality and quantity of the data on the intricate dynamics is extremely difficult since, in general, more accurate data are more costly. In the present study, two strategies are proposed to deal with the dilemma. To obtain accurate data, the CFD-CSD is adopted for precisely predicting the dynamics. To gain ample data, a novel data reproduction method is devised, where the obtained data are replicated for various situations while conserving the dynamics. With those data, the framework learns the control policy in various flow conditions and the learned policy is shown to have remarkable performance in controlling the flyer in complex flow fields., Comment: 53 pages, 13 figures, 1 algorithm, 1 table

Published
2021

11. Bimodal liquid biopsy for cancer immunotherapy based on peptide engineering and nanoscale analysis

Author

Bu, Jiyoon, Jeong, Woo-jin, Jafari, Roya, Kubiatowicz, Luke J., Nair, Ashita, Poellmann, Michael J., Hong, Rachel S., Liu, Elizabeth W., Owen, Randall H., Rawding, Piper A., Hopkins, Caroline M., Kim, DaWon, George, Daniel J., Armstrong, Andrew J., Král, Petr, Wang, Andrew Z., Bruce, Justine, Zhang, Tian, Kimple, Randall J., and Hong, Seungpyo

Published
2022
Full Text
View/download PDF

14. List of contributors

Author

Annaji, Manjusha, primary, Arnold, Robert D., additional, Babu, R. Jayachandra, additional, Bhadauria, Vivek, additional, Bharadwaj, Sudhir, additional, Cardoso, Valéria Maria de Oliveira, additional, Cassano, Roberta, additional, Chaudhari, Bhushan P., additional, Comparetti, Edson José, additional, Curcio, Federica, additional, Di Gioia, Maria Luisa, additional, Ding, Yingyue, additional, Ejderyan, Nora, additional, Ferreira, Leonardo Miziara Barboza, additional, Ferreira, Natália Noronha, additional, Gajbhiye, Kavita R., additional, Gajbhiye, Virendra, additional, García, Mónica C., additional, Hong, Seungpyo, additional, Hu, Quanyin, additional, Jadon, Pratap S., additional, Jadon, Rajesh S., additional, Javius-Jones, Kaila, additional, Kumar, Pramod, additional, Miranda, Renata Rank, additional, Mohanty, Ayeskanta, additional, Moudgil, Aliesha, additional, Nair, Ashita, additional, Narwade, Mahavir, additional, Park, In-Kyu, additional, Pawar, Anil T., additional, Poellmann, Michael J., additional, Poudel, Ishwor, additional, Salve, Rajesh, additional, Sampaio, Isabella, additional, Sanyal, Amitav, additional, Sanyal, Rana, additional, Sayed-Pathan, Nida Irfan, additional, Sharma, Manoj, additional, Sharma, Vikas, additional, Shende, Rajnigandha A., additional, Tiwari, Amit K., additional, Trombino, Sonia, additional, Uthaman, Saji, additional, and Zucolotto, Valtencir, additional

Published
2022
Full Text
View/download PDF

21. Prospective Characterization of Circulating Tumor Cell Kinetics in Patients With Oligometastatic Disease Receiving Definitive Intent Radiation Therapy.

Author

Sud, Shivani, Poellmann, Michael J., Hall, Jacob, Tan, Xianming, Bu, Jiyoon, Myung, Ja Hye, Wang, Andrew Z., Hong, Seungpyo, and Casey, Dana L.

Subjects
EPIDERMAL growth factor receptors, CELL adhesion molecules, WILCOXON signed-rank test, RADIOTHERAPY, PATIENT experience
Abstract

PURPOSE: There are currently no predictive molecular biomarkers to identify patients with oligometastatic disease (OMD) who will benefit from definitive-intent radiation therapy (RT). We prospectively characterized circulating tumor cell (CTC) kinetics in patients with OMD undergoing definitive-intent RT. METHODS: This prospective correlative biomarker study included patients with any solid malignancy ≤5 metastatic sites in ≤3 anatomic organ systems undergoing definitive-intent RT to all disease sites. Circulating tumor cells (CTCs) were captured and enumerated using a biomimetic cell rolling and nanotechnology-based assay functionalized with antibodies against epithelial cell adhesion molecule, against human epidermal growth factor receptor 2, and against epidermal growth factor receptor before and during RT and at follow-up visits up to 2 years post-RT. RESULTS: We enrolled 43 patients with a median follow-up of 14.3 months. The pretreatment CTC level (cells captured/mL) was not associated with the number of disease sites (median one metastatic site/patient, range 1-5) or metastasis location (bone, brain, visceral) on Wilcoxon signed-rank test, P >.05. Post-RT, 56% of patients received systemic therapy, and 72% of patients experienced subsequent local or systemic progression. For 90% of patients, a CTC level <15 within 130 days post-RT corresponded to a durable control of irradiated lesions. Patients with a favorable versus an unfavorable clearance profile experienced significantly longer progression-free survival after RT (median 13 v 4 months, log-rank test, P =.0011). On logistic regression, CTC level >15 at a given time point was associated with clinical disease progression within the subsequent 6 months (odds ratio 3.31, P =.007). In 26% of patients with disease progression, a CTC level >15 preceded radiographic or clinical progression. CONCLUSION: CTCs may serve as a biomarker for disease control in OMD and may predict disease progression before standard assessments for patients receiving diverse cancer-directed therapies. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

23. Automotive Process Reliability Prediction for 5,7nm using ML

Author

Jayaram, Srividya, primary, Lee, Hyung Joo, additional, Kim, Dongin, additional, Choi, Sanghyun, additional, Hong, Seungpyo, additional, Lee, Seungjae, additional, Kwak, Doohwan, additional, Paek, Seungwon, additional, Kwon, Minho, additional, Kim, Yeongdo, additional, Jung, Hyobe, additional, Kissiov, Ivan, additional, Torres, Andres, additional, Greeneltch, Nathan, additional, Tao, Melody, additional, and Lee, Ho, additional

Published
2023
Full Text
View/download PDF

28. Supplementary Figures 1-2, Supplementary Tables 1-2 from Multivalent Binding and Biomimetic Cell Rolling Improves the Sensitivity and Specificity of Circulating Tumor Cell Capture

Author

Myung, Ja Hye, primary, Eblan, Michael J., primary, Caster, Joseph M., primary, Park, Sin-Jung, primary, Poellmann, Michael J., primary, Wang, Kyle, primary, Tam, Kevin A., primary, Miller, Seth M., primary, Shen, Colette, primary, Chen, Ronald C., primary, Zhang, Tian, primary, Tepper, Joel E., primary, Chera, Bhishamjit S., primary, Wang, Andrew Z., primary, and Hong, Seungpyo, primary

Published
2023
Full Text
View/download PDF

29. Data from AXL Mediates Cetuximab and Radiation Resistance Through Tyrosine 821 and the c-ABL Kinase Pathway in Head and Neck Cancer

Author

McDaniel, Nellie K., primary, Iida, Mari, primary, Nickel, Kwangok P., primary, Longhurst, Colin A., primary, Fischbach, Samantha R., primary, Rodems, Tamara S., primary, Kranjac, Carlene A., primary, Bo, Amber Y., primary, Luo, Qianyun, primary, Gallagher, Meghan M., primary, Welke, Noah B., primary, Mitchell, Kaitlyn R., primary, Schulz, Alison E., primary, Eckers, Jaimee C., primary, Hu, Rong, primary, Salgia, Ravi, primary, Hong, Seungpyo, primary, Bruce, Justine Y., primary, Kimple, Randall J., primary, and Wheeler, Deric L., primary

Published
2023
Full Text
View/download PDF

30. Figure S5 from AXL Mediates Cetuximab and Radiation Resistance Through Tyrosine 821 and the c-ABL Kinase Pathway in Head and Neck Cancer

Author

McDaniel, Nellie K., primary, Iida, Mari, primary, Nickel, Kwangok P., primary, Longhurst, Colin A., primary, Fischbach, Samantha R., primary, Rodems, Tamara S., primary, Kranjac, Carlene A., primary, Bo, Amber Y., primary, Luo, Qianyun, primary, Gallagher, Meghan M., primary, Welke, Noah B., primary, Mitchell, Kaitlyn R., primary, Schulz, Alison E., primary, Eckers, Jaimee C., primary, Hu, Rong, primary, Salgia, Ravi, primary, Hong, Seungpyo, primary, Bruce, Justine Y., primary, Kimple, Randall J., primary, and Wheeler, Deric L., primary

Published
2023
Full Text
View/download PDF

31. Supplemental Figure Legends from AXL Mediates Cetuximab and Radiation Resistance Through Tyrosine 821 and the c-ABL Kinase Pathway in Head and Neck Cancer

Author

McDaniel, Nellie K., primary, Iida, Mari, primary, Nickel, Kwangok P., primary, Longhurst, Colin A., primary, Fischbach, Samantha R., primary, Rodems, Tamara S., primary, Kranjac, Carlene A., primary, Bo, Amber Y., primary, Luo, Qianyun, primary, Gallagher, Meghan M., primary, Welke, Noah B., primary, Mitchell, Kaitlyn R., primary, Schulz, Alison E., primary, Eckers, Jaimee C., primary, Hu, Rong, primary, Salgia, Ravi, primary, Hong, Seungpyo, primary, Bruce, Justine Y., primary, Kimple, Randall J., primary, and Wheeler, Deric L., primary

Published
2023
Full Text
View/download PDF

32. Table S1 from AXL Mediates Cetuximab and Radiation Resistance Through Tyrosine 821 and the c-ABL Kinase Pathway in Head and Neck Cancer

Author

McDaniel, Nellie K., primary, Iida, Mari, primary, Nickel, Kwangok P., primary, Longhurst, Colin A., primary, Fischbach, Samantha R., primary, Rodems, Tamara S., primary, Kranjac, Carlene A., primary, Bo, Amber Y., primary, Luo, Qianyun, primary, Gallagher, Meghan M., primary, Welke, Noah B., primary, Mitchell, Kaitlyn R., primary, Schulz, Alison E., primary, Eckers, Jaimee C., primary, Hu, Rong, primary, Salgia, Ravi, primary, Hong, Seungpyo, primary, Bruce, Justine Y., primary, Kimple, Randall J., primary, and Wheeler, Deric L., primary

Published
2023
Full Text
View/download PDF

33. Supplementary Figure Legends from Eradication of Acute Myeloid Leukemia with FLT3 Ligand–Targeted miR-150 Nanoparticles

Author

Jiang, Xi, primary, Bugno, Jason, primary, Hu, Chao, primary, Yang, Yang, primary, Herold, Tobias, primary, Qi, Jun, primary, Chen, Ping, primary, Gurbuxani, Sandeep, primary, Arnovitz, Stephen, primary, Strong, Jennifer, primary, Ferchen, Kyle, primary, Ulrich, Bryan, primary, Weng, Hengyou, primary, Wang, Yungui, primary, Huang, Hao, primary, Li, Shenglai, primary, Neilly, Mary Beth, primary, Larson, Richard A., primary, Le Beau, Michelle M., primary, Bohlander, Stefan K., primary, Jin, Jie, primary, Li, Zejuan, primary, Bradner, James E., primary, Hong, Seungpyo, primary, and Chen, Jianjun, primary

Published
2023
Full Text
View/download PDF

34. Supplemental Figures from Eradication of Acute Myeloid Leukemia with FLT3 Ligand–Targeted miR-150 Nanoparticles

Author

Jiang, Xi, primary, Bugno, Jason, primary, Hu, Chao, primary, Yang, Yang, primary, Herold, Tobias, primary, Qi, Jun, primary, Chen, Ping, primary, Gurbuxani, Sandeep, primary, Arnovitz, Stephen, primary, Strong, Jennifer, primary, Ferchen, Kyle, primary, Ulrich, Bryan, primary, Weng, Hengyou, primary, Wang, Yungui, primary, Huang, Hao, primary, Li, Shenglai, primary, Neilly, Mary Beth, primary, Larson, Richard A., primary, Le Beau, Michelle M., primary, Bohlander, Stefan K., primary, Jin, Jie, primary, Li, Zejuan, primary, Bradner, James E., primary, Hong, Seungpyo, primary, and Chen, Jianjun, primary

Published
2023
Full Text
View/download PDF

35. Supplemental Table 2 from Eradication of Acute Myeloid Leukemia with FLT3 Ligand–Targeted miR-150 Nanoparticles

Author

Jiang, Xi, primary, Bugno, Jason, primary, Hu, Chao, primary, Yang, Yang, primary, Herold, Tobias, primary, Qi, Jun, primary, Chen, Ping, primary, Gurbuxani, Sandeep, primary, Arnovitz, Stephen, primary, Strong, Jennifer, primary, Ferchen, Kyle, primary, Ulrich, Bryan, primary, Weng, Hengyou, primary, Wang, Yungui, primary, Huang, Hao, primary, Li, Shenglai, primary, Neilly, Mary Beth, primary, Larson, Richard A., primary, Le Beau, Michelle M., primary, Bohlander, Stefan K., primary, Jin, Jie, primary, Li, Zejuan, primary, Bradner, James E., primary, Hong, Seungpyo, primary, and Chen, Jianjun, primary

Published
2023
Full Text
View/download PDF

36. Data from Eradication of Acute Myeloid Leukemia with FLT3 Ligand–Targeted miR-150 Nanoparticles

Author

Jiang, Xi, primary, Bugno, Jason, primary, Hu, Chao, primary, Yang, Yang, primary, Herold, Tobias, primary, Qi, Jun, primary, Chen, Ping, primary, Gurbuxani, Sandeep, primary, Arnovitz, Stephen, primary, Strong, Jennifer, primary, Ferchen, Kyle, primary, Ulrich, Bryan, primary, Weng, Hengyou, primary, Wang, Yungui, primary, Huang, Hao, primary, Li, Shenglai, primary, Neilly, Mary Beth, primary, Larson, Richard A., primary, Le Beau, Michelle M., primary, Bohlander, Stefan K., primary, Jin, Jie, primary, Li, Zejuan, primary, Bradner, James E., primary, Hong, Seungpyo, primary, and Chen, Jianjun, primary

Published
2023
Full Text
View/download PDF

37. Supplemental Table 1 from Eradication of Acute Myeloid Leukemia with FLT3 Ligand–Targeted miR-150 Nanoparticles

Author

Jiang, Xi, primary, Bugno, Jason, primary, Hu, Chao, primary, Yang, Yang, primary, Herold, Tobias, primary, Qi, Jun, primary, Chen, Ping, primary, Gurbuxani, Sandeep, primary, Arnovitz, Stephen, primary, Strong, Jennifer, primary, Ferchen, Kyle, primary, Ulrich, Bryan, primary, Weng, Hengyou, primary, Wang, Yungui, primary, Huang, Hao, primary, Li, Shenglai, primary, Neilly, Mary Beth, primary, Larson, Richard A., primary, Le Beau, Michelle M., primary, Bohlander, Stefan K., primary, Jin, Jie, primary, Li, Zejuan, primary, Bradner, James E., primary, Hong, Seungpyo, primary, and Chen, Jianjun, primary

Published
2023
Full Text
View/download PDF

38. Supplemental Table 3 from Eradication of Acute Myeloid Leukemia with FLT3 Ligand–Targeted miR-150 Nanoparticles

Author

Jiang, Xi, primary, Bugno, Jason, primary, Hu, Chao, primary, Yang, Yang, primary, Herold, Tobias, primary, Qi, Jun, primary, Chen, Ping, primary, Gurbuxani, Sandeep, primary, Arnovitz, Stephen, primary, Strong, Jennifer, primary, Ferchen, Kyle, primary, Ulrich, Bryan, primary, Weng, Hengyou, primary, Wang, Yungui, primary, Huang, Hao, primary, Li, Shenglai, primary, Neilly, Mary Beth, primary, Larson, Richard A., primary, Le Beau, Michelle M., primary, Bohlander, Stefan K., primary, Jin, Jie, primary, Li, Zejuan, primary, Bradner, James E., primary, Hong, Seungpyo, primary, and Chen, Jianjun, primary

Published
2023
Full Text
View/download PDF

39. Dual Axl/ MerTK inhibitor INCB081776 creates a proinflammatory tumor immune microenvironment and enhances anti‐PDL1 efficacy in head and neck cancer

Author

Kostecki, Kourtney L., primary, Iida, Mari, additional, Wiley, Anne L., additional, Kimani, Stanley, additional, Mehall, Bridget, additional, Tetreault, Kaitlin, additional, Alexandridis, Roxana, additional, Yu, Menggang, additional, Hong, Seungpyo, additional, Salgia, Ravi, additional, Bruce, Justine Y., additional, Birge, Raymond B., additional, Harari, Paul M., additional, and Wheeler, Deric L., additional

Published
2023
Full Text
View/download PDF

41. Reliability Prediction for Automotive 5nm and 7nm Technology node by using Machine Learning based Solution

Author

Lee, Hyung Joo, primary, Kim, Dongin, additional, Choi, Sanghyun, additional, Hong, Seungpyo, additional, Kwak, Doohwan, additional, Jayaram, Srividya, additional, Paek, Seungwon, additional, Kwon, Minho, additional, Kim, Yeongdo, additional, Jung, Hyobe, additional, Kissiov, Ivan, additional, Tao, Melody, additional, Torres, Andres, additional, Greeneltch, Nathan, additional, and Lee, Ho, additional

Published
2023
Full Text
View/download PDF

48. Pose-Aware Smoothing Filter for Depth Images

Author

Hong, Seungpyo, Kim, Jinwook, Hutchison, David, Series editor, Kanade, Takeo, Series editor, Kittler, Josef, Series editor, Kleinberg, Jon M., Series editor, Kobsa, Alfred, Series editor, Mattern, Friedemann, Series editor, Mitchell, John C., Series editor, Naor, Moni, Series editor, Nierstrasz, Oscar, Series editor, Pandu Rangan, C., Series editor, Steffen, Bernhard, Series editor, Terzopoulos, Demetri, Series editor, Tygar, Doug, Series editor, Weikum, Gerhard, Series editor, Bebis, George, editor, Boyle, Richard, editor, Parvin, Bahram, editor, Koracin, Darko, editor, McMahan, Ryan, editor, Jerald, Jason, editor, Zhang, Hui, editor, Drucker, Steven M., editor, Kambhamettu, Chandra, editor, El Choubassi, Maha, editor, Deng, Zhigang, editor, and Carlson, Mark, editor

Published
2014
Full Text
View/download PDF

49. Dual Axl/MerTK inhibitor INCB081776 creates a proinflammatory tumor immune microenvironment and enhances anti‐PDL1 efficacy in head and neck cancer.

Author

Kostecki, Kourtney L., Iida, Mari, Wiley, Anne L., Kimani, Stanley, Mehall, Bridget, Tetreault, Kaitlin, Alexandridis, Roxana, Yu, Menggang, Hong, Seungpyo, Salgia, Ravi, Bruce, Justine Y., Birge, Raymond B., Harari, Paul M., and Wheeler, Deric L.

Subjects
HEAD & neck cancer, TUMOR microenvironment, KINASES, PROTEIN-tyrosine kinases, TUMOR growth, ORAL cancer
Abstract

Background: The tyrosine kinase receptors Axl and MerTK are highly overexpressed in head and neck cancer (HNC) cells, where they are critical drivers of survival, proliferation, metastasis, and therapeutic resistance. Methods: We investigated the role of Axl and MerTK in creating an immunologically "cold" tumor immune microenvironment (TIME) by targeting both receptors simultaneously with a small molecule inhibitor of Axl and MerTK (INCB081776). Effects of INCB081776 and/or anti‐PDL1 on mouse oral cancer (MOC) cell growth and on the TIME were evaluated. Results: Targeting Axl and MerTK can reduce M2 and induce M1 macrophage polarization. In vivo, INCB081776 treatment alone or with anti‐PDL1 appears to slow MOC tumor growth, increase proinflammatory immune infiltration, and decrease anti‐inflammatory immune infiltration. Conclusions: This data indicates that simultaneous targeting of Axl and MerTK with INCB081776, either alone or in combination with anti‐PDL1, slows tumor growth and creates a proinflammatory TIME in mouse models of HNC. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results